Hem › Plattenepitelcancer i huvud och hals › Virginia › Richmond
Kliniska studier för Plattenepitelcancer i huvud och hals i Richmond, VA
12 studier för Plattenepitelcancer i huvud och hals söker deltagare vid platser i och runt Richmond (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RekryterarFas 2/3
- Site #0129, Richmond
- Site #0138, Richmond
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RekryterarFas 3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RekryterarFas 2
- VCU Massey Comprehensive Cancer Center, Richmond
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekryterarFas 2
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RekryterarFas 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RekryterarFas 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekryterarFas 2
- Virginia Commonwealth University Massey Cancer Center, Richmond
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RekryterarFas 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Enhancing Oral Cancer Awareness
RekryterarFriska volontärer välkomna
- Virginia Commonwealth University, Richmond
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekryterarFas 3
- VCU Massey Cancer Center, Richmond
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
RekryterarFas 2
- Bon Secours, Richmond
- Virginia Commonwealth University, Richmond
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RekryterarFas 2
- Massey Cancer Center, Richmond
Plattenepitelcancer i huvud och hals-studier i andra städer
- Houston, TX47 studier
- Los Angeles, CA42 studier
- Boston, MA40 studier
- New York City, NY39 studier
- Nashville, TN39 studier
- St. Louis, MO28 studier
- Arlington, VA26 studier
- Philadelphia, PA26 studier
- Chicago, IL26 studier
- Atlanta, GA24 studier
- San Antonio, TX22 studier
- New Haven, CT22 studier
Andra studier i Richmond
- Bröstcancer26 studier
- Icke-småcellig lungcancer25 studier
- Prostatacancer19 studier
- Hjärtsvikt16 studier
- Lungcancer14 studier
- Hjärt-kärlsjukdom13 studier
- Kolorektal cancer13 studier
- Steatotisk leversjukdom12 studier
- Akut myeloid leukemi12 studier
- Metastaserande cancer12 studier
- Melanom11 studier
- Övervikt11 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.